Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus TESTOSTERONE PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus TESTOSTERONE PROPIONATE.
DELATESTRYL vs TESTOSTERONE PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Testosterone propionate is a short-acting androgen receptor agonist. It binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
50 to 200 mg intramuscularly every 2 to 4 weeks.
50-400 mg intramuscularly every 2-4 weeks. For androgen replacement, 50-100 mg IM every 2 weeks.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Clinical Note
moderateTestosterone propionate + Tranylcypromine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Tranylcypromine."
Clinical Note
moderateTestosterone propionate + Procarbazine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Procarbazine."
Clinical Note
moderateTestosterone propionate + Pirlindole
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Pirlindole."
Clinical Note
moderateTerminal half-life: 0.8–1.2 hours (rapid elimination due to short ester chain; requires frequent dosing).
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Renal: 90% (as glucuronide and sulfate conjugates); Fecal/Biliary: 10%.
Category C
Category D/X
Androgen
Androgen
Testosterone propionate + Moclobemide
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Moclobemide."